# A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

> **NCT07085104** · PHASE1 · RECRUITING · sponsor: **Allogene Therapeutics** · enrollment: 66 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (With and Without Nephritis)
- Idiopathic Inflammatory Myopathy
- Systemic Sclerosis

## Interventions

- **GENETIC:** ALLO-329
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07085104
- **Lead sponsor:** Allogene Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-13
- **Primary completion:** 2028-02
- **Final completion:** 2032-10
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07085104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07085104, "A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07085104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*